BNT162b2

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19InfluenzaKidney TransplantLiver DiseaseAutoimmune Disease

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

BNT162b2

BioNTech

Approved

292

Piperacillin/tazobactam

Pfizer

Preclinical

13

Orap

Teva

Preclinical

14

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

35

Aprotinin

Bayer

Preclinical

16

Antithrombin-III

Octapharma

Preclinical

17

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

18

MRNA COVID-19 Vaccine

Novartis

Preclinical

49

Tpa

UUniversity of Florida

Preclinical

110

Serology

UUniversity Hospital Center of Martinique

Preclinical

3Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COVID-1929 trials

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Completed·BioNTech·Phase 2/3·NCT04754594·726 enrolled

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

Completed·BioNTech·Phase 1/2·NCT04380701·512 enrolled

Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain

Completed·RRoyal College of Surgeons in Ireland - Medical University of Bahrain··NCT04993560·305 enrolled

Show 26 more trials

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Completed·BioNTech·Phase 3·NCT04816669·629 enrolled

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Completed·BioNTech·Phase 3·NCT04713553·1,574 enrolled

Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System

Unknown status·NNational and Kapodistrian University of Athens··NCT04743388·600 enrolled

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Completed·BioNTech·Phase 3·NCT04955626·16,372 enrolled

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

Completed·BioNTech·Phase 4·NCT04588480·160 enrolled

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

Unknown status·TThe University of Hong Kong·Phase 4·NCT05057182·300 enrolled

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting·CCanadian Immunization Research Network·Phase 2·NCT04894435·669 enrolled

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Unknown status·—·Phase 1/2·NCT05132855·340 enrolled

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05289037·1,270 enrolled

A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

Active, not recruiting·Pfizer··NCT06923137·1 enrolled

Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05124171·247 enrolled

Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)

Unknown status·TThe University of Hong Kong·Phase 4·NCT05057169·400 enrolled

Adaptive Immune Response to COVID-19 Vaccination

Unknown status·UUniversity Medicine Greifswald··NCT04826770·70 enrolled

Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers

Completed·SShaare Zedek Medical Center··NCT05308680·336 enrolled

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Completed·BioNTech·Phase 2/3·NCT04816643·11,837 enrolled

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

Completed·UUniversiteit Antwerpen·Phase 4·NCT06189040·580 enrolled

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

Active, not recruiting·BioNTech·Phase 3·NCT07222384·343 enrolled

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

Active, not recruiting·BioNTech·Phase 3·NCT07069309·760 enrolled

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Completed·BButantan Institute·Phase 2/3·NCT05354024·4,400 enrolled

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

Completed·Pfizer··NCT05020145·1,277,747 enrolled

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting·MMasaryk University··NCT04834869·30,000 enrolled

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

Completed·BioNTech·Phase 1·NCT05541861·383 enrolled

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

Completed·BioNTech·Phase 2/3·NCT05472038·1,453 enrolled

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

Completed·Pfizer··NCT05621239·260 enrolled

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Completed·BioNTech·Phase 2/3·NCT04368728·46,969 enrolled

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

Completed·—·Phase 4·NCT05343871·2,354 enrolled

Immunogenicity5 trials

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Completed·Pfizer·Phase 3·NCT04887948·570 enrolled

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Completed·BioNTech·Phase 2·NCT05004181·1,380 enrolled

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

Completed·BioNTech·Phase 2·NCT04649021·960 enrolled

Show 2 more trials

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

Unknown status·FFederal University of Espirito Santo·Phase 3·NCT05225285·1,120 enrolled

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Completed·BioNTech·Phase 3·NCT05310084·1,134 enrolled

Liver Disease1 trial

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Completed·HHumanity & Health Medical Group Limited·Phase 4·NCT04775069·232 enrolled

Kidney Transplant1 trial

Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients

Unknown status·MMedical University of Vienna·Phase 2·NCT05324319·200 enrolled

Immunocompromised1 trial

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

Completed·BioNTech·Phase 2·NCT04895982·124 enrolled

7 more indications

Influenza1 trial

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Completed·Pfizer·Phase 2·NCT06237049·644 enrolled

Vaccine1 trial

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Completed·BioNTech·Phase 2/3·NCT05997290·1,051 enrolled

Autoimmune Disease1 trial

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05000216·258 enrolled

Drug1 trial

Drug Use Investigation of COMIRNATY Intramuscular Injection

Completed·Pfizer··NCT04815031·14,570 enrolled

SARS-CoV-21 trial

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04889209·867 enrolled

Trial1 trial

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

Completed·BioNTech·Phase 2·NCT04949490·137 enrolled

Unspecified1 trial

Special Investigation of COMIRNATY in the Population With Underlying Diseases

Completed·Pfizer··NCT04880447·1,075 enrolled

Details

Drug Info

Related News